

Contents

Abbreviations *xv*

Contributors *xxi*

Part 1 **Constituents, History, International Control, Cultivation, and Phenotypes of Cannabis**

Ethan B. Russo

- 1 Constituents of *Cannabis Sativa* 3
Mahmoud ElSohly and Waseem Gul
- 2 The Pharmacological History of Cannabis 23
Ethan B. Russo
- 3 International Control of Cannabis 44
Alice P. Mead
- 4 Cannabis Horticulture 65
David J. Potter
- 5 The Chemical Phenotypes (Chemotypes) of *Cannabis* 89
Etienne de Meijer

Part 2 **Pharmacology, Pharmacokinetics, Metabolism, and Forensics**

Roger G. Pertwee

- 6 Known Pharmacological Actions of Delta-9-Tetrahydrocannabinol and of Four Other Chemical Constituents of Cannabis that Activate Cannabinoid Receptors 115
Roger G. Pertwee and Maria Grazia Cascio
- 7 Known Pharmacological Actions of Nine Nonpsychotropic Phytocannabinoids 137
Maria Grazia Cascio and Roger G. Pertwee
- 8 Effects of Phytocannabinoids on Neurotransmission in the Central and Peripheral Nervous Systems 157
Bela Szabo
- 9 Cannabinoids and Addiction 173
Eliot L. Gardner
- 10 Effects of Phytocannabinoids on Anxiety, Mood, and the Endocrine System 189
Sachin Patel, Matthew N. Hill, and Cecilia J. Hillard

- 11 Phytocannabinoids and the Cardiovascular System 208
Saoirse E. O’Sullivan
- 12 Phytocannabinoids and the Gastrointestinal System 227
Marnie Duncan and Angelo A. Izzo
- 13 Reproduction and Cannabinoids: Ups and Downs, Ins and Outs 245
Jordyn M. Stuart, Emma Leishman, and Heather B. Bradshaw
- 14 Phytocannabinoids and the Immune System 261
Guy A. Cabral, Erinn S. Raborn, and Gabriela A. Ferreira
- 15 Non-Phytocannabinoid Constituents of Cannabis and Herbal Synergy 280
John M. McPartland and Ethan B. Russo
- 16 Cannabinoid Pharmacokinetics and Disposition in Alternative Matrices 296
Marilyn A. Huestis and Michael L. Smith

Part 3 **Medicinal Cannabis and Cannabinoids: Clinical Data**

Ethan B. Russo

- 17 Self-Medication with Cannabis 319
Arno Hazekamp and George Pappas
- 18 Cannabis Distribution: Coffee Shops to Dispensaries 339
Amanda Reiman
- 19 Development of Cannabis-Based Medicines: Regulatory Hurdles/Routes in Europe and the United States 356
Alison Thompson and Verity Langfield
- 20 Licensed Cannabis-Based Medicines: Benefits and Risks 373
Stephen Wright and Geoffrey Guy
- 21 Synthetic Psychoactive Cannabinoids Licensed as Medicines 393
Mark A. Ware
- 22 Cannabinoids in Clinical Practice: A UK Perspective 415
William Notcutt and Emily L. Clarke

Part 4 **Approved Therapeutic Targets for Phytocannabinoids: Preclinical Pharmacology**

Marnie Duncan

- 23 Effect of Phytocannabinoids on Nausea and Vomiting 435
Erin M. Rock, Martin A. Sticht, and Linda A. Parker
- 24 Established and Emerging Concepts of Cannabinoid Action on Food Intake and their Potential Application to the Treatment of Anorexia and Cachexia 455
Luigia Cristino and Vincenzo Di Marzo
- 25 Pain 473
Barbara Costa and Francesca Comelli

- 26 Cannabis and Multiple Sclerosis 487
Gareth Pryce and David Baker

Part 5 **Some Potential Therapeutic Targets for
Phytocannabinoids**

Marnie Duncan

- 27 Neurodegenerative Disorders Other Than Multiple Sclerosis 505
*Javier Fernández-Ruiz, Eva de Lago, María Gómez-Ruiz, Concepción García,
Onintza Sagredo, and Moisés García-Arencibia*
- 28 Cannabidiol/Phytocannabinoids: A New Opportunity for Schizophrenia
Treatment? 526
Daniela Parolaro, Erica Zamberletti, and Tiziana Rubino
- 29 Phytocannabinoids as Novel Therapeutic Agents for Sleep Disorders 538
*Eric Murillo-Rodríguez, Lisa Aguilar-Turton, Stephanie Mijangos-Moreno,
Andrea Sarro-Ramírez, and Óscar Arias-Carrión*
- 30 Cannabis and Epilepsy 547
Claire M. Williams, Nicholas A. Jones, and Benjamin J. Whalley
- 31 Cardiovascular, Metabolic, Liver, Kidney, and Inflammatory Disorders 564
Pál Pacher and George Kunos
- 32 Phytocannabinoids and Skin Disorders 582
Sergio Oddi and Mauro Maccarrone
- 33 Phytocannabinoids in Degenerative and Inflammatory Retinal Diseases:
Glaucoma, Age-Related Macular Degeneration, Diabetic Retinopathy,
and Uveoretinitis 601
Heping Xu and Augusto Azuara-Blanco
- 34 Bone As a Target for Cannabinoid Therapy 619
Itai Bab
- 35 Cancer 626
Guillermo Velasco, Cristina Sánchez, and Manuel Guzmán

Part 6 **Recreational Cannabis: Sought-After Effects, Adverse
Effects, Designer Drugs, and Harm Minimization**

Wayne Hall

- 36 Desired and Undesired Effects of Cannabis on the Human Mind
and Psychological Well-Being 647
H. Valerie Curran and Celia J.A. Morgan
- 37 Recreational Cannabis: The Risk of Schizophrenia 661
Paul D. Morrison, Sagnik Bhattacharyya, and Robin M. Murray
- 38 Nonpsychological Adverse Effects 674
Franjo Grotenhermen

- 39** Harm Reduction Policies for Cannabis 692
Wayne Hall and Louisa Degenhardt
- 40** Cannabinoid Designer Drugs: Effects and Forensics 710
Brian F. Thomas, Jenny L. Wiley, Gerald T. Pollard, and Megan Grabenauer
- Index 731